Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

To avoid performative DEI, companies must embed equity into daily operations—hiring, leadership, pay and culture. Transparency, measurable goals and authentic storytelling from diverse voices build ...

Genetic testing company 23andMe isn’t going away, despite declaring bankruptcy. The company and nearly all of its assets, including its biobank of customer genetic samples, have been purchased by ...

Advances in DNA forensics are reigniting cold cases, solving mysteries after decades. From a 1993 assault of a teen girl in Alaska to a 52-year-old murder case in Utah, now there are answers. Take a ...

The Karen Read case is back in a Massachusetts courtroom on Monday as the trial enters a fifth week with an 18th day of ...

Regeneron, a biotechnology company, announced Monday that it will “acquire substantially all of the assets” of 23andMe ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy auction, and promised to prioritize the ethical use of DNA data from customers ...

It’s a bit eye-opening,” said study author Adam Soloff, an associate professor of cardiothoracic surgery at the University of ...

Today is the final matchday of the Icon League. The decision will be made as to which eight teams will compete in Berlin for ...

Regeneron’s offer, which is still subject to court and regulatory approvals, is a bet it can do what 23andMe couldn’t and ...

This article was translated into English by Artificial Intelligence. You can read the original version in 🇩🇪 here.Today is ...